ASCO21: Stick with standard of care for locally advanced cervical cancer

Adjuvant chemotherapy alongside the standard of care chemoradiation provides no benefit for locally advanced cervical cancer patients. Recent research, presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (4−8 June 2021), shows that the addition of chemotherapy after standard chemoradiation for patients with locally advanced cervical cancer bears no significant benefit for overall survival (OS). The study, lead by Linda Mileshkin of Peter McCallum Cancer Centre (Melbourne, Australia) confirms that the current standard of care (SOC) is the best available, preventing patients from experiencing unnecessary adverse events. For cervical cancer patients, the current SOC centers around cisplatin-based...